文献速递类风湿关节炎其他结缔组织病

利妥昔单抗治疗类风湿关节炎相关大颗粒淋巴细胞白血病:回顾性病例系列

Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series.
PubMed 文献 · Semin Arthritis Rheum · 2020-06-16

该多中心回顾性病例系列纳入14例符合ACR/EULAR 2010标准的RA并确诊LGLL的患者,评估利妥昔单抗的疗效与耐受性。结果显示总缓解率100%(8例完全缓解、6例部分缓解),中位缓解持续时间35个月,耐受性良好,无感染并发症。利妥昔单抗可能是RA相关LGLL的有价值治疗选择。

要点

  • 利妥昔单抗治疗RA相关LGLL总缓解率100%,其中完全缓解8例、部分缓解6例。
  • 中位缓解持续时间35个月(IQR 23.5–41),耐受性良好且无感染并发症。
  • 利妥昔单抗可作为RA相关LGLL的治疗选择,但需注意研究为回顾性小样本。

核心结论

  • 利妥昔单抗似乎是RA相关LGLL的有价值治疗选择。

研究设计与样本

  • 多中心回顾性病例系列,纳入14例RA相关LGLL患者(10例女性,平均年龄55.2±14.2岁)。
  • RA按ACR/EULAR 2010标准定义,LGLL按绝对LGL计数≥0.3×10^9/L且存在克隆性LGL扩增证据定义。

主要发现

  • LGLL诊断距RA诊断的中位时间为9.5年(IQR 3.25–15.5),13例为T-LGLL。
  • 利妥昔单抗为4例患者LGLL的一线治疗,既往治疗包括甲氨蝶呤(7例)、环磷酰胺(2例)、环孢素A(1例)或粒细胞集落刺激因子(4例)。
  • 利妥昔单抗单药治疗8例,联合甲氨蝶呤3例、粒细胞集落刺激因子2例或烷化剂1例;周期数1–11(中位6),给药方案异质性高。
  • 利妥昔单抗启动后中位缓解持续时间为35个月(IQR 23.5–41)。
  • 总缓解率100%:8例完全缓解(血细胞计数正常化且LGL≤0.3×10^9/L),6例部分缓解(血细胞计数改善但未完全正常化)。

关键数值与推荐

  • LGLL纳入标准:绝对LGL计数≥0.3×10^9/L,且流式细胞术、TCR-γ聚合酶链反应或Stat3突变证实克隆性LGL扩增。
  • 完全缓解定义为血细胞计数正常化且LGL≤0.3×10^9/L;部分缓解定义为血细胞计数改善但未完全正常化。

临床怎么用

  • 对于RA相关LGLL患者,利妥昔单抗可考虑作为治疗选项,尤其在一线或经其他治疗失败后。
  • 治疗期间需监测血细胞计数和LGL计数以评估缓解情况,本系列中耐受性良好且无感染并发症。

局限性

  • 回顾性病例系列,样本量小(14例),利妥昔单抗给药方案异质性高,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the efficacy and tolerance profile of rituximab in rheumatoid arthritis (RA)-associated large granular lymphocyte leukemia (LGLL). METHODS: Multicenter retrospective case series. Inclusion criteria were RA defined by the ACR/EULAR 2010 criteria and LGLL defined by absolute LGL count ≥ 0.3 × 109/L with evidence of an expanded clonal LGL population (flow cytometry, TCR-γ polymerase chain reaction, or Stat3 mutation). RESULTS: Fourteen patients (10 women, mean age 55.2 ± 14.2 years) included; 13 were seropositive for anti-cyclic citrullinated peptides (n = 11) or rheumatoid factor (n = 10). LGLL diagnosis was made 9.5 [IQR: 3.25;15.5] years after RA diagnosis. Thirteen patients had T-LGLL. Rituximab was the first-line therapy for LGLL for 4 patients. Previous treatment lines included methotrexate (n = 7), cyclophosphamide (n = 2), cyclosporin A (n = 1), or granulocyte colony-stimulating factor (n = 4). Rituximab was used in monotherapy (n = 8) or associated to methotrexate (n = 3), granulocyte colony-stimulating factor (n = 2), or alkylating agents (n = 1). The number of rituximab cycles ranged from 1 to 11 (median 6), with high heterogeneity in dosing regimens. Median duration response after rituximab initiation was 35 [IQR: 23.5;41] months. The overall response rate was 100%: 8 patients experienced complete response (normalization of blood count and LGL ≤ 0.3 × 109/L) and 6 experienced partial responses (improvement in blood counts without complete normalization). The tolerance profile was good, with no infectious complications. CONCLUSION: rituximab appears as a valuable therapeutic option for RA-associated LGLL.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Lobbes H, Dervout C, Toussirot E, et al. Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Semin Arthritis Rheum. 2020. PMID: 32920324. doi:10.1016/j.semarthrit.2020.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。